Results 141 to 150 of about 70,554 (222)

Second-line treatments for patients with programmed cell death protein 1-refractory cutaneous squamous cell carcinomas: a brief report. [PDF]

Oncologist
AlSharif H, Danchine V, Deekollu K, Hasanov M, Wu R, Haykal T, Faieta A, Verschraegen CF.   +7 more
europepmc   +1 more source

Correction: Ziranu et al. Navigating the Landscape of Liquid Biopsy in Colorectal Cancer: Current Insights and Future Directions. <i>Int. J. Mol. Sci.</i> 2025, <i>26</i>, 7619. [PDF]

Int J Mol Sci
Ziranu P, Pretta A, Saba G, Spanu D, Donisi C, Ferrari PA, Cau F, D'Agata AP, Piras M, Mariani S, Puzzoni M, Pusceddu V, Coghe F, Faa G, Scartozzi M.   +14 more
europepmc   +1 more source

Characterization of skin adverse events associated with cetuximab: real-world insights from the two global pharmacovigilance databases of FAERS and VigiAccess. [PDF]

Front Oncol
Li C, Gao Y, Guang M, Wu H, Li Y, Lu Y, Wei Y, Li X, Yang L.   +8 more
europepmc   +1 more source

Dacomitinib, a pan-inhibitor of ErbB receptors, suppresses growth and invasive capacity of chemoresistant ovarian carcinoma cells [PDF]

, 2017
et al,, Ghasemi, Reza
core   +2 more sources

Inhibition of α-1,3-mannosyltransferase sensitizes head and neck squamous cell carcinomas to cetuximab via endoplasmic reticulum stress. [PDF]

Cell Stress Chaperones
Hao Y, Deng G, Li B, Cheng L, Wang S, Yang Z.   +5 more
europepmc   +1 more source

Maculopapular-Type Drug Eruption Caused by Cetuximab. [PDF]

Cureus
Ikegawa N, Saito-Sasaki N, Sawada Y.
europepmc   +1 more source

BCL-xL as a therapeutic target in cetuximab-refractory colorectal cancer. [PDF]

Cell Death Dis
Asmanidou S, Thiel J, Ekstrom TL, Schueler J, Oswald E, Metzger P, Blaumeiser AC, Boerries M, Wiebl LM, Schiffler R, Tamas R, Essmann F, Dong M, Johnsen SA, Kontermann RE, Olayioye MA.   +15 more
europepmc   +1 more source

Dalpicilib combined with cetuximab in patients with HPV-negative, anti-PD-1-resistant recurrent or metastatic head and neck squamous cell carcinoma: A phase II trial. [PDF]

Nat Commun
Ju H, Wu Y, Shi C, Xia R, Song H, Ma X, Liu Y, Sun L, Zhu L, Chen L, Sun S, He Y, Ren G, Hu J.   +13 more
europepmc   +1 more source

Multi-agent chemotherapy for refractory head and neck cancer. [PDF]

J Chin Med Assoc
Ho IW, Chen TH, Chang PM, Tai SK, Chu PY, Lin JC, Yang MH.   +6 more
europepmc   +1 more source

Sequential salvage systemic therapy after immunotherapy in head and neck cancer: a real-world study. [PDF]

Front Oncol
Cabezas-Camarero S, Merino-Menéndez S, Cabrera-Martín MN, Pérez-Alonso P, Sotelo MJ, Pérez-Segura P.   +5 more
europepmc   +1 more source